Inactive Instrument

Clinigen Group plc

Equities

CLIN

GB00B89J2419

Clinigen : Change of Joint Broker

January 13, 2017 at 05:10 am EST

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it has appointed RBC Capital Markets to act as its Joint Broker with immediate effect. Numis Securities Limited continues to act as Nominated Adviser and Joint Broker to the Company.

-Ends-

Contact Details

Clinigen Group plc
Tel: +44 (0) 1283 495 010
Shaun Chilton, Group Chief Executive Officer
Martin Abell, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations

Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)

RBC Capital Markets
Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas / Jack Wood

Instinctif Partners (media relations)
Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell
Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.

For more information, please visit www.clinigengroup.com

Clinigen Group plc published this content on 13 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 January 2017 10:10:19 UTC.

Original documenthttp://www.clinigengroup.com/media/news/change-of-joint-broker

Public permalinkhttp://www.publicnow.com/view/CBBC4FB71C5DC73D824FD813BCF34BADD5A3C121

Latest news about Clinigen Group plc

Clinigen Launches NaviGATE an Educational Programme for Rare Disease Patients and Organizations	23-09-12	CI
CNX Therapeutics Limited acquired Cardioxane® (dexrazoxane), Savene® (dexrazoxane), Totect® (dexrazoxane) and Ethyol®, four cancer support therapies from Clinigen Limited.	23-08-09	CI
Clinigen Limited Reports Earnings Results for the Full Year Ended June 30, 2022	23-05-08	CI
Adragos Pharma GmbH completed the acquisition of Lamda Laboratories S.A. from Clinigen Limited.	23-04-02	CI
Adragos Pharma GmbH signed a definitive agreement to acquire Lamda Laboratories S.A. from Clinigen Limited.	23-03-19	CI
Iovance Biotherapeutics, Inc. entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited for approximately £210 million.	23-01-22	CI
Clinigen Group plc acquired Drug Safety Navigator, LLC.	22-12-30	CI
Clinigen Notes Results from the MIROCALS Trial Investigating Low Dose Proleukin® (Aldesleukin) in Patients with Amyotrophic Lateral Sclerosis	22-12-08	CI
Clinigen Group plc agreed to acquire Drug Safety Navigator, LLC.	22-11-28	CI
Clinigen Expands US Site Capacity in Response to Growing Demand for Clinical Supplies Management Services	22-05-24	CI
Triton Funds Company Completes Takeover Of Clinigen	22-04-04	MT
Triton Fund V SCSP, Triton Fund V L.P., Triton Fund V F&F No. 5 SCSp, Triton Fund V F&F No.3 L.P., Triton Fund V F&F L.P., Triton Fund V F&F No. 2 L.P., Triton Fund V F&F 4 SCSp and Triton C Investment A L.P., managed by Triton completed the acquisition of Clinigen Group plc.	22-04-03	CI
UK's High Court Approves Clinigen's Takeover	22-03-31	MT
Clinigen's Fiscal H1 Profit Sinks As Sales, Administrative Costs Rise	22-02-23	MT
Clinigen Group plc Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-23	CI
Scentre Group CEO/Managing Director to Step Down End-September; Shares Fall 5%	22-02-22	MT
Scentre Signals Higher Distribution, Faster Earnings Growth in Fiscal Year 2022	22-02-22	DJ
Clinigen Expects to Complete $1.8 Billion Sale to Triton in Early April	22-02-16	MT
Clinigen Group plc Signs Distribution Agreement with Deciphera Pharmaceuticals	22-02-09	CI
Clinigen Group Declares the Voting Results	22-02-08	CI
Clinigen Group plc Issues Open Letter to the Shareholders	22-01-20	CI
Clinigen Postpones Court, General Meetings following Increased Takeover Offer	22-01-18	MT
Global markets live: Credit Suisse, Unilever, Pfizer, Volkswagen, Triton...	22-01-17
UK's Clinigen agrees to sweetened $1.8 billion Triton take-private deal	22-01-17	RE
Clinigen Receives Sweetened $1.8 Billion Takeover Bid From Triton	22-01-17	MT

Chart Clinigen Group plc

Duration

Period

More charts

Company Profile

Clinigen Group plc is a United Kingdom-based pharmaceutical services and products company. The Company's principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. It operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). It operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.

Sector

More about the company